Welcome to our dedicated page for Statera Biopharma news (Ticker: STAB), a resource for investors and traders seeking the latest updates and insights on Statera Biopharma stock.
Statera Biopharma, Inc. (STAB) appears in news coverage as a clinical-stage biopharmaceutical company focused on immunotherapies that target autoimmune diseases, neutropenia/anemia, emerging viruses, and cancers. Its disclosures emphasize a proprietary platform of toll-like receptor (TLR) drugs designed to rebalance the body's immune system and restore homeostasis, which shapes the types of developments reported in STAB-related news.
News items about Statera Biopharma frequently highlight progress and challenges in its clinical and corporate trajectory. On the scientific side, releases describe programs such as STAT-201 for Crohn's disease, hematology applications involving Entolimod and STAT-600/Entolimod, STAT-401 for pancreatic cancer, STAT-300 series candidates for multiple cancers and inflammation, and STAT-205 for COVID-19, along with potential expansion into other autoimmune and inflammatory conditions.
Another recurring theme in STAB news is the company's TLR5 agonist program. A Business Wire announcement reported that Tivic Health Systems, Inc. acquired worldwide exclusive license rights from Statera Biopharma to the late-stage TLR5 agonist Entolimod for acute radiation syndrome, with options on additional indications and a derivative, Entalasta. That coverage also noted FDA Fast Track and Orphan Drug designations for Entolimod in radiation-related indications and described the transfer of certain Statera team members to Tivic Health.
Corporate and capital markets updates are also prominent in Statera Biopharma news. Releases have addressed Nasdaq listing determinations, notices of filing delinquency, the completion and filing of Form 10-K and Form 10-Q reports, and efforts to move from OTC Pink Sheets to the OTCQB Venture Marketplace. Additional items include financing-related agreements and the appointment of an independent registered public accounting firm.
Strategic collaboration announcements, such as a binding Memorandum of Understanding with Holobeam Technologies for access to holographic diagnostic imaging and therapeutic technology, and a non-binding letter of intent for a proposed merger with Worksite Labs, further contribute to the news flow. Investors and observers following STAB news can review these updates to understand how Statera Biopharma's immunotherapy platform, licensing arrangements, regulatory status, and potential transactions evolve over time.
Statera Biopharma (Nasdaq: STAB) will participate in the Benzinga Virtual Healthcare Small Cap Conference on September 29-30, 2021. CEO Michael K. Handley will present on September 29, 2021, from 3:40 - 4:00 p.m. ET. The conference registration can be accessed online. Following the presentation, a webcast will be available in the Investor Relations section of Statera's website. Statera, formerly known as Cytocom, focuses on innovative therapies targeting immune restoration and homeostasis, with clinical programs addressing various diseases.
Statera Biopharma, Inc. (Nasdaq: STAB) will participate in the 2021 Cantor Virtual Global Healthcare Conference from September 27-30, 2021. CEO Michael K. Handley will hold a virtual fireside chat on September 30, 2021, from 12:40 to 1:10 p.m. ET. A webcast of this discussion will be available on the company's Investor Relations section post-conference. Statera focuses on immune therapies for autoimmune diseases, cancers, and emerging viruses, leveraging a proprietary platform with TLR agonists, and has ongoing clinical programs for conditions like Crohn's disease and COVID-19.
Statera BioPharma, Inc. (Nasdaq: STAB) announced its management team, led by President and CEO Michael K. Handley, will ring the Nasdaq Closing Bell on September 2, 2021. This event celebrates the company's new name and ticker symbol after completing a reverse merger on July 27, 2021, transitioning from Cytocom. Statera focuses on developing next-generation immune therapies targeting various diseases, enhancing the immune system's balance. The company expresses optimism regarding its future and ongoing clinical programs for autoimmune conditions, cancer, and COVID-19.